WHAT IS CLAIMED:

1. Use of a first composition in the preparation of a medicament for use in combination therapy with a second composition for treating cancer in a human subject, wherein the first composition comprises a chimeric Newcastle disease virus (NDV), wherein the chimeric NDV comprises a packaged genome comprising a transgene encoding human interleukin-12 ("IL-12"), wherein the transgene encodes a human IL-12 p40 subunit and a human IL-12 p35 subunit, wherein said second composition comprises an antibody that binds to human PD-1, and blocks the interaction between human PD-1 and its ligands, PD-L1 and PD-L2, and wherein said medicament is to be administered in combination with the second composition.

2. The use of claim 1, wherein the chimeric NDV comprises an NDV backbone of LaSota strain.

3. The use of claim 1, wherein the chimeric NDV comprises an NDV backbone of La Sota strain and the packaged genome comprises a nucleotide sequence encoding a mutated F protein with the amino acid mutation L289A, wherein the mutated F protein is incorporated into the virion of the chimeric NDV.

4. The use of claim 3, wherein the chimeric NDV does not comprises a heterologous sequence encoding a heterologous protein other than the human IL-12 and the mutated F protein.

5. The use of any one of claims 1 to 4, wherein the IL-12 comprises the amino acid sequence set forth in SEQ ID NO:39.

6. The use of claim 5, wherein the transgene comprises the nucleotide sequence set forth in SEQ ID NO: 61.

7. The use of any one of claims 1 to 4, wherein the IL-12 comprises the amino acid sequence set forth in SEQ ID NO:22.

8. The use of claim 7, wherein the transgene comprises the nucleotide sequence set forth in SEQ ID NO: 26.

9. The use of any one of claims 1 to 4, wherein the IL-12 comprises the amino acid sequence set forth in SEQ ID NO:43 or 42.

10. The use of claim 9, wherein the transgene comprises the nucleotide sequence set forth in SEQ ID NO: 63, 68, 53, or 66.

11. The use of any one of claims 1 to 4, wherein the IL-12 p40 subunit comprises the amino acid sequence set forth in SEQ ID NO: 38 or 23 and the IL-12 p35 subunit comprises the amino acid sequence set forth in SEQ ID NO: 41 or 25.

12. The use of any one of claims 1 to 11, wherein the packaged genome comprises a transcription unit for an NDV NP gene, a transcription unit for an NDV P gene, a transcription unit for an NDV M gene, a transcription unit for an NDV F gene, a transcription unit for an NDV HN gene, and a transcription unit for an NDV L gene, and wherein the transgene is inserted between the NDV P gene and the NDV M gene of the packaged genome.

13. The use of claim 1, wherein the packaged genome comprises the nucleotide sequence set forth in SEQ ID NO:51.

14. The use of claim 1, wherein the packaged genome comprises the nucleotide sequence set forth in SEQ ID NO:52 or 60.

15. The use of any one of claims 1 to 14, wherein the antibody is pembrolizumab.

16. The use of any one of claims 1 to 14, wherein the antibody is nivolumab.

17. The use of any one of claims 1 to 14, wherein the antibody is MEDI0680.

18. The use of any one of claims 1 to 14, wherein the antibody comprises:

(a) a variable light chain region (VLCR) CDR1 comprising the amino acid sequence RASKGVSTSGYSYLH (SEQ ID NO: 1), a VLCR CDR2 comprising the amino acid sequence LASYLES (SEQ ID NO: 2), and a VLCR CDR3 comprising the amino acid sequence QHSRDLPLT (SEQ ID NO: 3), and

(b) a variable heavy chain region (VHCR) CDR1 comprising the amino acid sequence NYYMY (SEQ ID NO: 6), a VHCR CDR2 comprising the amino acid sequence GINPSNGGTNFNEKFKN (SEQ ID NO: 7), and a VHCR CDR3 comprises the amino acid sequence RDYRFDMGFDY (SEQ ID NO: 8).

19. The use of any one of claims 1 to 14, wherein the antibody comprises:

(a) a VLCR comprising the amino acid sequence EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYL ESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIK (SEQ ID NO: 4); and

(b) a VHCR comprising the amino acid sequence QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPS NGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDY WGQGTTVTVSS (SEQ ID NO: 9).

20. The use of any one of claims 1 to 14, wherein the antibody comprises:

(a) a light chain comprising the amino acid sequence EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYL ESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIKRTVAAP SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 5); and

(b) a heavy chain comprising the amino acid sequence QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPS NGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDY WGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGAL TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYG PPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDG VEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISK AKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO: 10).

21. The use of any one of claims 1 to 14, wherein the antibody comprises:

(a) a VLCR CDR1 comprising the amino acid sequence RASQSVSSYLA (SEQ ID NO: 11), a VLCR CDR2 comprising the amino acid sequence DASNRAT (SEQ ID NO: 12), a VLCR CDR3 comprising the amino acid sequence QQSSNWPRT (SEQ ID NO: 13), and

(b) a VHCR CDR1 comprising the amino acid sequence NSGMH (SEQ ID NO: 16), a VHCR CDR2 comprising the amino acid sequence VIWYDGSKRYYADSVKG (SEQ ID NO: 17), and a VHCR CDR3 comprising the amino acid sequence NDDY (SEQ ID NO: 18)

22. The use of any one of claims 1 to 14, wherein the antibody comprises:

(a) a VLCR comprising the amino acid sequence EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIK (SEQ ID NO: 14); and

(b) a VHCR comprising the amino acid sequence QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSS (SEQ ID NO: 19).

23. The use of any one of claims 1 to 14, wherein the antibody comprises:

(a) a light chain comprising the amino acid sequence EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 15); and

(b) a heavy chain comprising the amino acid sequence QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREP

QVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS FFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO: 20).

24. The use of any one of claims 1 to 23, wherein the first composition is administered to the subject intratumorally or intra-nodally, and the second composition is administered to the subject intravenously or subcutaneously.

25. The use of claim 24, wherein the subject exhibits cutaneous or subcutaneous tumors or tumors within the lymph node.

26. The use of any one of claims 1 to 25, wherein the cancer is melanoma, kidney cancer, lung cancer, bladder cancer, ovarian cancer, hepatocellular carcinoma, pancreatic cancer, renal cancer, colorectal cancer, breast cancer, head and neck cancer, non-Hodgkin lymphoma or Hodgkin lymphoma, or a solid tumor selected from the group consisting of melanoma, sarcoma, uterine cancer, gastric cancer, esophageal cancer, liver cancer, brain cancer, head and neck squamous cell carcinoma, and breast carcinoma.

27. The use of claim 26, wherein the lung cancer is non-small cell lung cancer, the head and neck cancer is squamous cell carcinoma of the head and neck, the renal cancer is renal cell carcinoma, the colorectal cancer is colorectal carcinoma, or the breast cancer is breast carcinoma.

28. The use of any one of claims 1 to 25, wherein the cancer is melanoma, non-small cell lung cancer, head and neck cancer (HNSCC head and neck squamous cell carcinoma), Urothelial cancer, Triple negative breast cancer, gastric cancer, gastroesophageal junction adenocarcinoma , classical Hodgkin lymphoma, non-Hodgkin lymphoma, diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, mesothelioma, ovarian cancer, small cell lung cancer, esophageal cancer, nasopharyngeal cancer, anal cancer, biliary tract cancer, colorectal cancer, ER+/HER2- breast cancer, cervical cancer, thyroid cancer, salivary cancer, endometrial cancer, prostate cancer, glioblastoma, microsatellite instability-high (MSI-H) or mismatch repair deficient cancer (tissue agnostic), or tumors with high tumor mutational burden (tissue agnostic).

29. The use of any one of claims 1 to 28, wherein the cancer is unresectable.

30. The use of any one of claims 1 to 28, wherein the cancer comprises a dermal, subcutaneous, or nodal metastasis.

31. The use of any one of claims 1 to 30, wherein a biopsy of the cancer is PD-L1-positive.

32. The use of claim 31, wherein the biopsy has a tumor proportion score of at least 1%.

33. The use of claim 31, wherein the biopsy has a combined positive score of at least 1.

34. The use of any one of claims 1 to 33, wherein the subject is refractory or unresponsive to monotherapy treatment with an antibody that binds to PD-1 and blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.

35. The use of any one of claims 1 to 33, wherein the subject is refractory to monotherapy treatment with an antibody that binds to PD-1 and blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.

36. The use of claim 34 or 35, wherein the antibody that binds PD-1 is pembrolizumab.

37. The use of any one of claims 1 to 33, wherein the subject is refractory or unresponsive to monotherapy treatment with an antibody to PD-L1.

38. The use of any one of claims 1 to 37, wherein the cancer is relapsed.

39. Use of a first composition in the preparation of a medicament for use in combination therapy with a second composition for treating cancer in a human subject, wherein the first composition comprises a chimeric Newcastle disease virus (NDV) of La Sota strain, wherein the chimeric NDV comprises a packaged genome comprising a transgene encoding human interleukin-12 (IL-12) comprising the amino acid sequence set forth in SEQ ID NO:39 or SEQ ID NO:22, wherein the packaged genome comprises a transcription unit for an NDV NP gene, a transcription unit for an NDV P gene, a transcription unit for an NDV

M gene, a transcription unit for an NDV F gene, a transcription unit for an NDV HN gene, and a transcription unit for an NDV L gene, wherein the transgene is inserted between the NDV P gene and the NDV M gene of the packaged genome, and the packaged genome comprises a nucleotide sequence encoding a mutated F protein with the amino acid mutation L289A, wherein the mutated F protein is incorporated into the virion of the chimeric NDV, wherein said second composition comprises pembrolizumab, and wherein the first composition is to be administered to the subject intratumorally or intra-nodally, and the second composition is to be administered to the subject intravenously or subcutaneously.

40. Use of a first composition in the preparation of a medicament for use in combination therapy with a second composition for treating cancer in a human subject, wherein the first composition comprises a chimeric Newcastle disease virus (NDV) of La Sota strain, wherein the chimeric NDV comprises a packaged genome comprising a transgene encoding human interleukin-12 (IL-12), wherein the transgene comprises the nucleotide sequence set forth in SEQ ID NO:61 or SEQ ID NO:26, wherein the packaged genome comprises a transcription unit for an NDV NP gene, a transcription unit for an NDV P gene, a transcription unit for an NDV M gene, a transcription unit for an NDV F gene, a transcription unit for an NDV HN gene, and a transcription unit for an NDV L gene, wherein the transgene is inserted between the NDV P gene and the NDV M gene of the packaged genome, and the packaged genome comprises a nucleotide sequence encoding a mutated F protein with the amino acid mutation L289A, wherein the mutated F protein is incorporated into the virion of the chimeric NDV, wherein said second composition comprises pembrolizumab, and wherein the first composition is to be administered to the subject intratumorally or intra-nodally, and the second composition is to be administered to the subject intravenously or subcutaneously.

41. The use of claim 39 or 40, wherein the packaged genome of the chimeric NDV does not comprises a heterologous sequence encoding a heterologous protein other than the human IL-12 thereof and the mutated F protein.

42. The use of any one of claims 39 to 41, wherein the subject is refractory to monotherapy treatment with an antibody that binds to PD-1 and blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.

43. The use of any one of claims 39 to 41, wherein the subject is refractory to monotherapy treatment with an antibody that binds to PD-L1.